


# Accepted Manuscript

Fungal treatment of metoprolol and its recalcitrant metabolite metoprolol acid in hospital wastewater: biotransformation, sorption and ecotoxicological impact

Adrián Jaén-Gil, Francesc Castellet-Rovira, Marta Llorca, Marta Villagrasa, Montserrat Sarrà, Sara Rodríguez-Mozaz, Damià Barceló



PII: S0043-1354(19)30011-9

DOI: <https://doi.org/10.1016/j.watres.2018.12.054>

Reference: WR 14351

To appear in: *Water Research*

Received Date: 1 August 2018

Revised Date: 21 December 2018


Accepted Date: 22 December 2018

Please cite this article as: Jaén-Gil, A., Castellet-Rovira, F., Llorca, M., Villagrasa, M., Sarrà, M., Rodríguez-Mozaz, S., Barceló, D., Fungal treatment of metoprolol and its recalcitrant metabolite metoprolol acid in hospital wastewater: biotransformation, sorption and ecotoxicological impact, *Water Research*, <https://doi.org/10.1016/j.watres.2018.12.054>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>





1 **Fungal treatment of metoprolol and its recalcitrant metabolite metoprolol acid in**  
2 **hospital wastewater: biotransformation, sorption and ecotoxicological impact**

3 Adrián Jaén-Gil<sup>a</sup>, Francesc Castellet-Rovira<sup>b</sup>, Marta Llorca<sup>c</sup>, Marta Villagrasa<sup>a</sup>,  
4 Montserrat Sarrà<sup>b</sup>, Sara Rodríguez-Mozaz<sup>a\*</sup>, Damià Barceló<sup>a, c</sup>

5

6 <sup>a</sup> *Catalan Institute for Water Research (ICRA), H<sub>2</sub>O Building, Scientific and Technological Park*  
7 *of the University of Girona, Emili Grahit 101, E-17003 Girona, Spain*

8 <sup>b</sup> *Chemical, Biological and Environmental Engineering Department, Universitat Autònoma de*  
9 *Barcelona (UAB), E-08193 Bellaterra, Spain*

10 <sup>c</sup> *Water and Soil Quality Research Group, Department of Environmental Chemistry, (IDAEA-*  
11 *CSIC), Jordi Girona 18-26, E-08034 Barcelona, Spain*

12

13

14

15

16

17

18 *\* Corresponding author: Sara Rodríguez-Mozaz*

19 *E-mail: srodriguez@icra.cat*

20 *Tel.: +34 972 18 33 80*

21 *Catalan Institute for Water Research (ICRA)*

22 *Scientific and Technologic Park of the University of Girona*

23 *Emili Grahit 101, E-17003 Girona, Spain*

## 24 ABSTRACT

25 Hospital wastewater (HWW) effluents represent an important source of contaminants  
26 such as pharmaceutical compounds and their human metabolites. To better evaluate  
27 dedicated treatment of hospital effluents for pollutant mitigation, not only the parent  
28 compounds should be considered but also the intermediates generated during  
29 treatment. The metabolite metoprolol acid (MTPA) has been found in urban  
30 wastewaters at higher concentration than its parent compound metoprolol (MTP), being  
31 more recalcitrant to biodegradation. The aim of this study was to investigate  
32 degradation, transformation and sorption of the  $\beta$ -blocker MTP, and its recalcitrant  
33 metabolite MTPA, during water treatment based on the fungi *Ganoderma lucidum* (GL),  
34 *Trametes Versicolor* (TV) and *Pleurotus ostreatus* (PO). Fourteen intermediates were  
35 identified in MTP biotransformation while five of them also attributed to MTPA  
36 biodegradation and two to MTPA only. Their identification allowed their correlation in  
37 separate biotransformation pathways suggested. The highest degradation rate of  
38 metoprolol (up to 51%) and metoprolol acid (almost 77%) was found after 15-days  
39 treatment with *Ganoderma lucidum*, with an increase in toxicity up to 29% and 4%  
40 respectively. This fungus was further selected for treating real HWW in a batch  
41 fluidized bed bioreactor (FBB). Treated wastewater and fungal biomass samples were  
42 used to evaluate the distribution of the target compounds and the intermediates  
43 identified between solid and liquid phases. While similar elimination capabilities were  
44 observed for the removal of metoprolol, and even higher for its persistent metabolite  
45 metoprolol acid, the extent on compound transformation diminished considerably  
46 compared with the study treating purified water: a high level of the persistent  $\alpha$ -HMTP  
47 and TP240 were still present in effluent samples (15% and 6% respectively), being  
48 both TPs present at high proportion (up to 28%) in fungal biomass. This is the first time  
49 that pharmaceutical TPs have been investigated in the fungal biomass.

50 **Keywords:** metoprolol, metoprolol acid, fungal water treatment, fungal biomass,  
51 suspect screening, transformation products.

## 52 1. Introduction

53 In recent years, the presence of pharmaceuticals (PhACs) in the environment has been  
54 recognized as one of the most concerning environmental issues (Verlicchi et al., 2012).  
55 Every day, large quantities of wastewaters containing a broad variety of chemicals  
56 coming from domestic and industrial uses are discharged into sewage system. Hospital  
57 wastewater (HWW) in particular, have been recognized as important source of PhACs,  
58 where they can be found at several  $\mu\text{g/L}$  (Carraro et al., 2016; Verlicchi et al., 2015,  
59 2010). Since there is not a specific directive or guideline in Europe for treating HWW  
60 before its disposal (Rodriguez-Mozaz et al., 2018), these effluents are usually released  
61 into municipal sewer system without applying any previous water pretreatment. Their  
62 contribution at municipal wastewater treatment plants (WWTPs) range approximately  
63 from 0.2% to 2% of total wastewater volume (Carraro et al., 2016). Considering that  
64 conventional WWTPs are not designed to completely eliminate these emerging  
65 contaminants (Ratola et al., 2012), they can pass through and find their way into the  
66 environment. Therefore, the use of alternative on-site wastewater treatments prior to  
67 sewer discharge has been highly recommended (Verlicchi et al., 2015), where a  
68 decrease of up to 90% on total pharmaceutical load can be achieved (Pauwels and  
69 Verstraete, 2006).

70 Among the different wastewater treatments, activated sludge is currently considered  
71 the treatment of choice (Bletsou et al., 2015). However, alternative treatments based  
72 on fungi have been reported to be effective in the removal of micropollutants, thanks to  
73 its unspecific ligninolytic systems and intracellular enzymatic complexes (Asgher et al.,  
74 2008). *Trametes versicolor*, *Ganoderma lucidum* and *Pleurotus ostreatus* (part of the  
75 Basidiomycota division and the Agaricomycetes class) have been successfully applied

76 for the elimination of certain pharmaceuticals (Cruz-Morató et al., 2014; Llorca et al.,  
77 2018; Marco-Urrea et al., 2009; Palli et al., 2017) with the overall load elimination of  
78 83% in optimal conditions (Cruz-Morató et al., 2014). Among the extracellular enzymes  
79 responsible of pharmaceutical degradation lignin peroxidase, manganese peroxidase  
80 and laccase are the most important ones (Asgher et al., 2008). The low specificity of  
81 these enzymes make the selected fungi suitable for bioremediation processes.  
82 However, while some authors have successfully applied this kind of treatment for  
83 pharmaceutical removal (Cruz-Morató et al., 2014; Llorca et al., 2018; Marco-Urrea et  
84 al., 2009; Palli et al., 2017), less attention has been paid to the transformation products  
85 (TPs) generated, which may sometimes be more persistent or toxic than the parent  
86 compound (Escher and Fenner, 2011; Jaén-Gil et al., 2018). Considering that not only  
87 PhACs are present in HWW effluents but also their human metabolites, the European  
88 Medicines Agency (EMA) has set guidelines on environmental risk assessment  
89 indicating that relevant metabolites are those excreted in  $\geq 10\%$  of the administered  
90 dose (Wharf and Kingdom, 2010). Even so, unknown intermediates from these  
91 metabolites can also be generated during wastewater treatment. Therefore, their  
92 transformation pathways should also be investigated to better understand pollutant  
93 mitigation and properly evaluate wastewater treatment processes.

94 Among the different PhACs therapeutic families of present in HWWs,  $\beta$ -blockers have  
95 been widely detected in such effluents due to the its high consumption for hypertension  
96 and cardiovascular diseases (Hughes et al., 2013). Some of them are included into the  
97 20 most commonly encountered pharmaceuticals in European waters (Hughes et al.,  
98 2013). For instance, metoprolol (MTP) is largely prescribed in Germany reaching  
99 values of almost 100 tons per year (Scheurer et al., 2010) and has been detected in  
100 wastewater in the range of 160-2000 ng/L (Maurer et al., 2007; Scheurer et al., 2010),  
101 with low elimination rates in conventional WWTPs (usually between 0% and 36%)  
102 (Lacey et al., 2012; Rubirola et al., 2014; Scheurer et al., 2010). On the other hand, it is

103 well-known that MTP is mainly eliminated in human body, up to 85% throughout  
104 hepatic oxidative metabolism, and transformed into O-desmethylnmetoprolol (O-DMTP),  
105  $\alpha$ -hydroxymetoprolol ( $\alpha$ -HMTP) and metoprolol acid (MTPA) metabolites. Among them,  
106 MTPA is the major compound eliminated via renal excretion around 60-65% (Escher et  
107 al., 2006; Kern et al., 2010), while the other metabolites can also be present in urine  
108 but at much lower concentration (Godbillon and Duval, 1984). This metabolite has been  
109 found *ca.* one order of magnitude higher concentrations than MTP in wastewater  
110 (Mamo et al., 2018; Rubirola et al., 2014), and its persistence during biological  
111 treatment has been reported in some studies (Radjenović et al., 2008; Rubirola et al.,  
112 2014), indicating its potential environmental relevance. Although many studies have  
113 focused on the elimination of MTP in wastewater effluents (Benner and Ternes, 2009;  
114 Cavalcante et al., 2015; Romero et al., 2016a, 2016b, 2015; Šojić et al., 2012; Wilde et  
115 al., 2014), only few data was found concerning its elimination during HWW treatment  
116 (Wilde et al., 2014), and even less testing its fungal biotransformation by fungal  
117 treatments (Ma et al., 2007). Moreover, none of the studies exploring the intermediates  
118 generated after MTP degradation has investigated the biotransformation of the main  
119 metabolite MTPA (Benner and Ternes, 2009; Cavalcante et al., 2015; Koba et al.,  
120 2016; Ma et al., 2007; Romero et al., 2016b, 2016a, 2015; Rubirola et al., 2014;  
121 Slegers et al., 2006; Šojić et al., 2012; Tay et al., 2013; Wilde et al., 2014).

122 In this study, degradation, transformation and sorption of MTP and its main metabolite  
123 MTPA were investigated in batch experiments with three fungi (*Ganoderma lucidum*,  
124 *Trametes versicolor* and *Pleurotus ostreatus*) by using liquid chromatography coupled  
125 to high resolution mass spectrometry (LC-LTQ-Orbitrap-MS/MS) through a suspect  
126 screening methodology. Treated wastewater and fungal biomass samples were used to  
127 evaluate the presence the target compounds and their TPs in both compartments. To  
128 the authors' knowledge, this is the first time that pharmaceutical TPs have been

129 investigated in fungal biomass, as well as the first time that biodegradation and  
130 biotransformation of MTPA has been studied in wastewater treatment.

## 131 **2. Materials and Methods**

### 132 **2.1. Chemicals and fungi**

133 Metoprolol tartrate salt (MTP) (Sigma-Aldrich); O-desmethylnmetoprolol (O-DMTP),  
134 metoprolol acid (MTPA) and  $\alpha$ -hydroxymetoprolol ( $\alpha$ -HMTP) (Toronto Research  
135 Chemicals); and atenolol- $d^7$  internal standard (CDN isotopes, Quebec, Canada) were  
136 purchased at high purity grade (> 98%). Ultra-pure water and acetonitrile LiChrosolv  
137 grade were supplied by Merck (Darmstadt, Germany). Working standard solutions were  
138 prepared in methanol/water (10:90, v/v). Solid phase extraction (SPE) cartridges Oasis  
139 HLB (60 mg, 3 mL) were from Waters Corporation (Milford, MA, USA).

140 Three different species of fungi from different collections were used: *Ganoderma*  
141 *lucidum* (WRF) FP-58537-Sp strain, United States Department of Agriculture, Madison,  
142 Wis. Collection); *Trametes versicolor* (WRF) (American Type Culture Collection #42530  
143 strain); and *Pleurotus ostreatus* was isolated from a fruiting body collected from rotting  
144 wood, identified through molecular analysis (Palli et al., 2017). *G. lucidum* and *T.*  
145 *versicolor* were subcultured on 2% malt extract agar petri plates while *P. ostreatus* was  
146 maintained on malt extract agar (MEA) plates (ATCC medium 325).

147 Pellet immobilization was achieved for all the fungi following the same procedure  
148 described previously (Blánquez et al., 2004). The pellets obtained by this process were  
149 washed with sterile deionized water and kept (if needed) in a 0.8% NaCl solution at 4  
150 °C.

### 151 **2.2. Fungal degradation experiments**



152 Experiments for MTP and MTPA elimination were performed in 250 mL Erlenmeyer  
153 flasks for 15 days with *G. lucidum*, *T. versicolor* and *P. ostreatus* fungi. For each  
154 fungus, experiments were carried out in triplicate by spiking selected compounds  
155 individually at a concentration of 2.5 mg/L in 100 mL of a defined medium, which  
156 consists of 8 g/L of glucose, 3.3 g/L of ammonium tartrate, 1.168 g/L of 2,2-  
157 dimethylsuccinate buffer, and 1 and 10 mL of a micronutrient and macronutrient  
158 solution from Kirk medium (Kirk et al., 1978). The pH was adjusted to 4.5 before  
159 sterilization at 121 °C for 30 min. Flasks were inoculated with pellets equivalent to  $3.5 \pm$   
160 0.8 g/L dry cell weight (DCW). To better assess the different biotransformation  
161 regarding the parent compounds selected (MTP and MTPA), the experimental  
162 procedure was performed for each compound separately. Additionally, abiotic control  
163 (same conditions described above but without biomass), live control (same conditions  
164 but without spiking compounds) and killed control experiments (same conditions but  
165 with heat-killed biomass) were also performed in triplicate and used to evaluate other  
166 potential physicochemical processes affecting pharmaceutical transformation and  
167 sorption. All experiments were performed under natural light conditions and  
168 temperature maintained at 25 °C. Samples were collected along 15 days and further  
169 centrifuged in glass vials to separate fungus from water phase. Then, 100  $\mu$ L of internal  
170 standard were added to achieve a final concentration of 100  $\mu$ g/L. Finally, samples  
171 were directly injected into the LC-LTQ-Orbitrap-MS/MS system (see the following  
172 section 2.4.).

### 173 **2.3. Fluidized bed bioreactor experiments**

174 Biodegradation, biotransformation and sorption of target pollutants and their TPs were  
175 investigated along 7 days in a non-sterilized 0.5 L air-pulsed fluidized bed bioreactor  
176 (FBB) treating HWW. The HWW was collected directly from the sewer manifold of Sant  
177 Joan de Déu Hospital (Barcelona, Catalonia) and pretreated with coagulation-

178 flocculation, which involved the addition of coagulant HyflocAC50 at 43 mg/L during 2  
179 min at 200 rpm and flocculant HimolocDR3000 at 4.8 mg/L for 15 min at 20 rpm  
180 (Derypol, Barcelona, Catalonia). Wastewater characteristics were: pH range of 7.8-8.7;  
181 chemical oxygen demand (COD) of 633-1012 mg/L O<sub>2</sub>; N-NH<sub>4</sub><sup>+</sup> of 9.9-36 mg/L and total  
182 suspended solids (TSS) of 193-284 mg/L. Finally, the pH of wastewater was adjusted  
183 to 4.5. Concerning bioreactor operation, the FBB experiments were inoculated in  
184 duplicate with *G. lucidum* mycelial pellets equivalent to 2.5 ± 0.8 g/L dry cell weight.  
185 Electrovalve was set to supply 1 s of air pulse every 2 s and the aeration rate was 0.8  
186 L/min. Glucose and ammonium chloride were supplied at 7.5 C/N molar ratio from  
187 concentrated stock solutions in fed-batch operation mode at consumption rate (0.8 g  
188 C<sub>6</sub>H<sub>12</sub>O<sub>6</sub> g DCW<sup>-1</sup> and 0.19 g N<sub>4</sub>Cl g DCW<sup>-1</sup>). In an attempt to reproduce more realistic  
189 conditions, MTP and MTPA were spiked simultaneously at a concentration level of 2.0  
190 ± 0.5 µg/L each. Samples were taken at time 0 and 7 days of operation and further  
191 centrifuged in glass vials to separate fungus from water phase. To avoid possible  
192 experimental changes during the experiments, *G. lucidum* biomass samples were  
193 taken at final experimental time of 7 days only. Then, HWW samples were treated  
194 following an SPE methodology described elsewhere (Gros et al., 2012). On the other  
195 hand, fungal biomass samples were treated following the solid extraction methodology  
196 reported previously (Lucas et al., 2018). Detailed sample preparation procedures are  
197 presented in Supplementary Material, S1. Both, water and fungal extracts were  
198 reconstituted in 100 µL of methanol/water (10:90, v/v) containing internal standard to a  
199 final concentration of 100 µg/L in vial for further injection into LC-LTQ-Orbitrap-MS/MS  
200 (see the following section 2.4.)

#### 201 **2.4. Instrumental analysis**

202 Samples collected from flasks experiments and FBB extracts (from wastewater and  
203 fungal biomass) were analyzed in a liquid-chromatography system coupled to a hybrid

204 linear ion trap (LTQ)-Orbitrap mass spectrometer. Detection of MTP and MTPA as well  
205 as their tentative TPs was performed via a suspect screening methodology using a  
206 ready-made list of accurate masses selected from literature, included prior to sample  
207 analysis for MS/MS fragmentation (Table S1). Data was acquired in data dependent  
208 acquisition mode (DDA) using collision-induced dissociation (CID) and higher-energy  
209 collisional dissociation (HCD) fragmentation energies. For those compounds where  
210 reference standards were available (MTP, MTPA, O-DMTP and  $\alpha$ -HMTP), verification  
211 was performed by comparison with retention times and MS/MS ion fragmentation  
212 patterns. When reference standards were not commercially available, confirmation was  
213 performed via structural elucidation of MS/MS fragmentation patterns using Mass  
214 Frontier 7.0 software (Thermo Scientific). More detailed information of sample analysis  
215 is presented in Supplementary Material, S2. After identification, peak area  
216 measurement of MTP, MTPA and TPs was performed using the equations presented in  
217 Section 2.5. Additionally, accurate quantification of MTP and MTPA in water and  
218 biomass of HWW experiments was also performed (see Table S2 for analytical quality  
219 parameters).

## 220 **2.5. Data processing**

### 221 **2.5.1 Elimination of MTP and MTPA in fungal flask experiments**

222 The removal efficiency of MTP and MTPA for the three fungus selected were evaluated  
223 along the performed flasks experiments. The contribution of abiotic processes to  
224 elimination was calculated using Eq. (1), where  $A_0$  is the area at initial time and  $A_x^{ac}$  is  
225 the area measured at a particular sampling time in the abiotic control experiments:

$$226 \quad \text{Abiotic degradation (\%)} = \frac{A_0 - A_x^{ac}}{A_0} \quad \text{Eq. (1)}$$

227 Elimination by sorption was calculated using Eq. (2), where  $A_x^{kc}$  is the area at the same  
 228 particular sampling time in killed control experiments:

$$229 \quad \text{Sorption (\%)} = \frac{A_x^{ac} - A_x^{kc}}{A_0} \quad \text{Eq. (2)}$$

230 Finally, biodegradation was calculated using Eq. (3), where  $A_x^{de}$  is the area measured  
 231 in fungal degradation experiments at the certain experimental time:

$$232 \quad \text{Biodegradation (\%)} = \frac{A_x^{kc} - A_x^{de}}{A_0} \quad \text{Eq. (3)}$$

### 233 **2.5.2 Distribution of pollutants in liquid and biomass solid phases in the fluidized** 234 **bed bioreactors**

235 The distribution of spiked pollutants (MTP and MTPA) in HWW and fungal biomass  
 236 was calculated using Eq. (4) where  $A_x^l$  is the chromatographic area in liquid phase at a  
 237 specific experimental time, and  $A_0^l$  is the area of MTP or MTPA at initial time (all  
 238 estimated for the total FBB volume of 0.5 L) corrected by the corresponding recovery  
 239 value in HWW (quality parameters and concentration values are presented in Table  
 240 S2):

$$241 \quad \text{Presence in liquid phase (\%)} = \left( \frac{A_x^l}{A_0^l} \right) \quad \text{Eq. (4)}$$

242 The presence of MTP and MTPA in solid phase was calculated as it can be seen in Eq.  
 243 (5), where  $A_x^s$  is the corresponding area in the solid phase at a certain experimental  
 244 time (estimated for the total biomass of 2.5 g/L dry weight), and  $A_0^l$  is again the spiked  
 245 area in liquid phase at initial time (estimated for the total FBB volume of 0.5 L). All  
 246 areas were also corrected by the recovery values calculated in the corresponding liquid  
 247 and solid phases (quality parameters and concentration values are presented in Table  
 248 S2):

249 
$$\text{Presence in solid phase (\%)} = \left( \frac{A_x^S}{A_0^L} \right) \quad \text{Eq. (5)}$$

250 Since reference standards for TPs were not available, a proper quantification was not  
251 feasible. However, in order to provide tentative values of the presence of TPs in HWW  
252 and fungal biomass, Eq. (4) and Eq. (5) were used considering  $A_0^L$  as the sum of MTP  
253 and MTPA areas corrected by the mean recovery value of these compounds in liquid  
254 (91%) and solid biomass (46%) phases.

## 255 **2.6. Toxicity evaluation**

256 The ISO 11348-3 protocol (ISO, 1998) for testing bacterial bioluminescence was  
257 applied to evaluate acute toxicity of samples along the experiments using the Microtox®  
258 Model 500 Toxicity Analyzer (Strategic Diagnostics Inc. Newark, DE, US). For this  
259 purpose, all flasks and FBB water samples were centrifuged in glass vials to remove  
260 any biomass fragments or suspended solids interfering. Then, the percentage of decay  
261 on emitted light was measured when samples were in contact with the bioluminescent  
262 bacterium *V. fischeri*. The 50% effective concentration ( $EC_{50}$ ) was measured after 15  
263 min (expressed in dilution percentage). Changes in toxicity ( $EC_{50}$ ) at a particular  
264 experimental time were calculated in percentage as  $(EC_{50(\text{initial})} - EC_{50(x)})/EC_{50(\text{initial})}$   
265 adapted from Font et al., 2003.

## 266 **3. Results and Discussion**

### 267 **3.1 Elimination processes of MTP and MTPA in fungal flasks experiments**

268 Elimination processes such as biodegradation, fungal sorption and other abiotic  
269 processes of MTP and its main metabolite MTPA were evaluated in flasks experiments.  
270 Fig. 1 summarizes MTP and MTPA presence decay in the different experiments  
271 performed as well as the sum of TPs measured for the three-fungal species tested  
272 (whose identity is described in Section 3.2 and Supplementary Material, S5). As

273 expected, MTP, MTPA and TPs were not detected in live (non-spiked) control  
274 conditions. Abiotic control experiments showed negligible MTP and MTPA elimination  
275 which evidences their high chemical stability. In fungal degradation experiments, partial  
276 elimination of MTP was achieved reaching removal values as high as 51%, 49% and  
277 17% in water treated with *G. lucidum*, *T. versicolor* and *P. ostreatus* respectively, with  
278 high contribution of sorption processes (ca.  $25 \pm 3\%$  of initial compound amount) in all  
279 species tested. Only in the experiments with *G. lucidum*, biodegradation is pointed out  
280 as the main removal mechanism reaching values up to 28% (Table 1), whereas it was  
281 lower in the experiments performed with *T. versicolor* (21%) and not existing in the  
282 case of *P. ostreatus*. In any case, overall elimination achieved for MTP by fungi  
283 (between 17% and 51%) was lower than that obtained in former activated sludge flasks  
284 experiments where MTP was spiked at similar concentration (1 mg/L) and biomass (3  
285 gTSS/L), and where total MTP elimination was achieved after 96 hours (Rubirola et al.,  
286 2014). Nevertheless, despite from the removal of target pollutants, the generation and  
287 elimination of their corresponding TPs should also be considered to properly assess  
288 the efficiency of fungal treatment (intermediates are further discussed in Section 3.2  
289 and Supplementary Material, S5). To this respect, higher generation of TPs was  
290 observed for those experiments exhibiting higher MTP biodegradation rates (Fig. 1). In  
291 general, the highest generation of TPs was observed after 7 days of treatment and  
292 maintained until the end of the experiments. This fact indicates that, even though MTP  
293 was eliminated during the experiments, the elimination of the TPs generated was not  
294 accomplished in the same manner.

295 MTPA was more extensively removed than MTP yielding values up to 77%, 54% and  
296 35% in water treated with *G. lucidum*, *T. versicolor* and *P. ostreatus* respectively (Fig.  
297 1). Nonetheless, results reveal lower contribution to sorption processes compared to  
298 those values obtained in MTP experiments; biomass sorption percentages ranged from  
299 0% to 11% (Table 1). These levels should be explained by the different partition

300 coefficients of both compounds. However, the predicted distribution coefficients  $\log D$   
301 values for MTP and MTPA at pH 4.5 were quite similar, indicating their low tendency to  
302 be present in solid phase (-1.48 for MTP and -1.27 for MTPA calculated with  
303 ChemAxon ("ChemAxon Chemicalize Calculator," 2018)) and without a direct  
304 correlation ( $\log D$ ) with actual sorption of MTP and MTPA in fungal biomass.  
305 Biodegradation was thus pinpointed as the main removal mechanism for MTPA with  
306 the three fungi tested (Fig. 1). Among them, *G. lucidum* was pointed out as the most  
307 effective fungus reaching biodegradation values around 63%, being 11% accounted as  
308 sorption contribution to total removal (Table 1). *T. versicolor* and *P. ostreatus* attained  
309 lower biodegradation rates of about 48% and 32% percentages, respectively. In  
310 accordance to this, *G. lucidum* was also reported as the most efficient fungus for  
311 biodegradation of venlafaxine and O-desmethylenlafaxine (spiked at 5 mg/L) with total  
312 removal values up to 70% and 100%, respectively (Llorca et al., 2018). The optimal  
313 removal of MTPA with these fungi needs to be highlighted since it was previously  
314 reported as a concerning metabolite, given its high persistence in previous batch  
315 activated sludge experiments, generated from the biodegradation of MTP spiked at 1  
316 mg/L (Rubirola et al., 2014), and from atenolol spiked at 10 mg/L (Radjenović et al.,  
317 2008). As in the case of MTP experiments, the highest concentrations of MTPA TPs  
318 were measured when the highest MTPA biodegradation rates were registered; *i.e.* after  
319 9 and 15 days of treatment with all three fungi tested. Actually, high levels of MTP and  
320 MTPA intermediates (between 7% and 31% for MTP degradation and from 51% to  
321 100% for MTPA transformation, Fig. 1) were always detected at the end of  
322 corresponding experiments, which underlines the inability of fungal treatments for total  
323 compound mineralization, and the generation of a large quantity of new chemical  
324 structures. Thus, their identification, toxicity as well as the elucidation of their  
325 transformation pathways are necessary to evaluate the performance of a particular  
326 water treatment.

## 327 **3.2 Identification and monitoring of suspected TPs in fungal flasks experiments**

328 A suspect screening methodology for the detection of tentative TPs was applied based  
329 on the comparison of accurate masses obtained after compound detection with those  
330 gathered from literature. Since multiple peaks can be detected for the same exact  
331 mass, comparison with retention times (when reference standards are available) and  
332 chemical structure elucidation based on the MS/MS data were performed for  
333 confirmation purposes. A summary of accurate masses, elemental composition and  
334 tentative chemical structures of TPs detected are presented in Table S3. In accordance  
335 to the European Commission Decision 2002/657/EC, measurements were always  
336 within mass error of 5 ppm by means of MS<sup>n</sup> analysis. This criterion was considered  
337 enough to assign the elemental compositions and chemical structures of both parent  
338 and fragment ions. Firstly, fragmentation scans were elucidated by using those data  
339 acquired in CID fragmentation energy. However, this approach was considered  
340 insufficient to discern among similar TP structures. Therefore, HCD fragmentation  
341 energy was necessary to obtain complementary small fragments to finally confirm the  
342 tentative chemical structures. Once the structures were elucidated (Table S3),  
343 proposed degradation pathways were tentatively suggested and presented in Fig. 2.  
344 Those compounds with relative abundances higher than 1% were chosen for further  
345 consideration.

### 346 **3.2.1 Metoprolol biotransformation**

347 Fourteen major TPs were tentatively identified along fungi experiments from MTP  
348 biodegradation (Fig. 2). Relative TP percentages obtained for the three fungi tested are  
349 presented in Fig. 3. Among them, no intermediates were detected in abiotic conditions  
350 indicating the absence of any chemical degradation in further MTP elimination.  
351 Regarding fungal degradation experiments, the highest number of intermediates was  
352 detected after 15 days of treatment, when MTP had already been eliminated in all fungi



353 tested. Among them, TP238,  $\alpha$ -HMTP, TP282A, TP284, TP300, TP316 and TP134  
354 were classified as the major compounds detected coming from biotransformation  
355 mechanisms such as hydroxylation, oxidation and O-dealkylation (Bletsou et al., 2015).  
356 Although these TPs were widely detected in water treated with advanced oxidation  
357 processes (AOPs) (Cavalcante et al., 2015; Romero et al., 2016a; Wilde et al., 2014),  
358 the presence of the cytochrome P450 in fungi species was also suggested to generate  
359 them through enzymatic oxidation (Meunier et al., 2004). Moreover, the enzymes  
360 known as lignin peroxidases (LiP) and manganese-dependent peroxidases (MnP),  
361 also present in these fungal species, allow to carry out oxidative reactions such as  
362 carbon-carbon bond cleavages, demethylations, hydroxylations and benzylic alcohol  
363 oxidations (Barr and Aust, 1994).

364 In this study, the most significant degradation pathway, with generation of O-DMTP,  
365 TP240, TP238 and TP254 (Fig. 3), was identified in all fungi experiments, being  
366 especially notorious for those experiments with higher MTP biodegradation rates.  
367 Among them, TP238 was identified as the most persistent compound generated at 9%  
368 in the experiments with *G. lucidum*, and further transformed into TP254 (at 1%) after 15  
369 days of treatment. The formation of TP238 and TP240 were suggested after O-  
370 demethylation of MTP and further benzylic hydroxylation through the formation of a  
371 radical intermediate (after hydrogen abstraction and stabilized by resonance) of O-  
372 DMTP (also a human metabolite), detected at low concentration (up to 1% in  
373 *T. versicolor*). The rapid metabolization/biodegradation of O-DMTP in fungal  
374 experiments was in agreement with the results obtained in MTP degradation  
375 experiments with activated sludge, where the complete elimination of this TP was  
376 achieved after 48 h and a maximum concentration observed at 24 h operation  
377 (Rubirola et al., 2014). Further TP240 was also classified as a non-recalcitrant  
378 compound being detected at < 1%, however, O-DMTP was rapidly transformed into  
379 TP238 and TP254 in pure water. This last compound generated from the oxidation of

380 the aldehyde intermediate onto a carboxylic acid (in TP254) could be related to lignin  
381 peroxidases (LiP), manganese-dependent peroxidases (MnP) and/or cytochrome P450  
382 enzymes (Barr and Aust, 1994). A secondary degradation pathway was suggested with  
383 generation of  $\alpha$ -HMTP (another human metabolite generated after pharmaceutical  
384 consumption) followed by TP282A and TP298.  $\alpha$ -HMTP was found up to 5% in the  
385 experiments with *G. lucidum* and *T. versicolor*, where higher MTP biodegradation rates  
386 were observed. Further oxidation to TP282A and hydroxylation to TP298 was found  
387 with gradually lower occurrence comparing to  $\alpha$ -HMTP, which indicates the great  
388 persistence of  $\alpha$ -HMTP in fungal treatments, as well as in treatments performed with  
389 activated sludge (Rubirola et al., 2014). The last degradation pathway was  
390 characterized by the multiple oxidations of aromatic ring with formation of the  
391 intermediates TP284, TP300 and TP316, especially notorious throughout *T. versicolor*  
392 biodegradation. As it can be seen, the TP284 was generated and rapidly transformed  
393 to the subsequent TP300. The same profile was identified for this last TP being  
394 practically degraded at 15-days treatment to further generate TP316 up to 6%. These  
395 compounds could be generated from the unspecific and aromatic peroxygenase (UPO)  
396 also secreted by fungi, able to catalyse the hydroxylation of aromatic rings and alkyl  
397 chains (Hofrichter et al., 2010). Finally, other TPs worth to mention are TP134, formed  
398 from the transformation of those TPs with secondary amine structure (Fig. 2). Since it  
399 can be designed as a residual TP, its formation might be considered as an indicator to  
400 evaluate the extent of mineralization through O-dealkylation catalysed by cytochrome  
401 P450 monooxygenases (Urlacher and Girhard, 2012). In fact, the presence of TP134  
402 increased at the same time as biodegradation values of the parent compound (Table  
403 1). Another remarkable aspect to consider in fungal degradation experiments is that  
404 MTPA is not generated from MTP biodegradation whereas in activated sludge  
405 experiments was identified as the major TP, with levels up to 40% of initial MTP  
406 concentration after 96 h treatment (Rubirola et al., 2014); and when atenolol was

407 spiked at 10 mg/L in 26 days of treatment reaching values up to 60% (Radjenović et  
408 al., 2008). Likewise, MTP biotransformation into MTPA metabolite achieved conversion  
409 values of 59% in experiments performed with fungus *Cunninghamella blakesleeana*  
410 (Ma et al., 2007). Since the presence of TP226C and TP282B were also negligible in  
411 MTP fungal experiments, it seems that this transformation pathway does not take place  
412 along fungal water treatments with GL, TV and PO. In fact, the high relative  
413 percentages of TP238 compared to the other TPs formed denoted a significant  
414 prioritization of its transformation pathway instead of the metabolic pathway that  
415 favours the generation of MTPA metabolite. However, the rapid degradation rate of  
416 MTPA intermediates prior to sampling at 3 days of treatment cannot be discarded. This  
417 difference on metabolite formation depending on the treatment used was also observed  
418 in man, dogs and rats where the same MTP metabolites were recovered but in different  
419 relative proportions (Borg et al., 1975). Therefore, the presence of such recalcitrant  
420 MTPA in biological based treatment technologies was thus depending on the  
421 organisms used for water treatment.

### 422 **3.2.2 Metoprolol acid biotransformation**

423 Seven major TPs were tentatively identified during MTPA biodegradation experiments  
424 (Fig. 2). Relative TP percentages obtained for the three fungi tested are presented in  
425 Fig. 3. Also in this case, no intermediates were detected in abiotic conditions indicating  
426 the absence of factors involved in MTPA transformation. Among them TP238, TP240,  
427 TP254 and TP134 were classified as the major compounds detected in fungal  
428 degradation experiments. As expected, the highest presence of TPs was found after 15  
429 days of treatment when the maximum concentration of MTPA had already been  
430 eliminated. In contrast to MTP biodegradation experiments, only three biodegradation  
431 pathways were suggested. However, the presence of O-DMTP was not detected while  
432 the generation of TP240 and TP238 were much higher reaching values up to 60%.

433 Their formation might be also related to a benzylic hydroxylation through the formation  
434 of the radical intermediate after hydrogen abstraction (Barr and Aust, 1994). Such high  
435 levels allowed the further generation of TP254 up to 15% whereas this compound was  
436 only detected at 1% in MTP degradation experiments. The higher biodegradation of  
437 MTPA and the reduced number of transformation pathways compared to MTP might  
438 explain the higher amount of the TPs detected in MTPA experiments. On the other  
439 hand, the generation of TP282B and TP226C was only detected when treating MTPA  
440 in fungal experiments, but at low concentration levels. This fact indicates that the  
441 transformation pathway involving the generation of TP238 was also prioritized when  
442 treating MTPA in single experiments, as observed in MTP fungal biodegradation. In this  
443 case, the methylation of MTPA to TP282B could be mediated by the  
444 methyltransferases enzymes present in fungi (Wessjohann et al., 2013) while N-  
445 dealkylation of TP226C could be catalyzed by cytochrome P450 monooxygenases  
446 (Urlacher and Girhard, 2012). Otherwise, the high levels of TP134 (more than 2.5 times  
447 higher than in MTP experiments), previously suggested as an indicator of  
448 mineralization, pointing out the more extended progress in the transformation pathway  
449 in fungi experiments but still the incomplete elimination of MTPA TPs.

### 450 **3.3 Toxicity tests in flasks experiments**

451 Toxicity was monitored in water samples to detect potential toxic TPs generated along  
452 the fungal flask experiments. A slightly increase on toxicity values along MTP  
453 experiments was observed in all fungi tested (29% in *G. lucidum*, 15% in *T. versicolor*  
454 and 24% in *P. ostreatus*, Table S4). In the case of MTPA experiments, a slight increase  
455 on toxicity at the end of the experiment was also observed (4%, 11% and 29% for GL,  
456 TV and PO respectively). These results are slightly higher than those reported in batch  
457 experiments using activated sludge at 1 mg/L of MTP and 3 gTSS/L during 72 h, where  
458 no significant differences among toxic units were observed (Rubirola et al., 2014). In

459 the later study, the metabolite O-DMTP from MTP elimination was reported to be the  
460 most toxic compound detected ( $EC_{50}$  of 18 mg/L). However, in the present study this  
461 TP was always below than 1.5% of the MTP and MTPA initial concentration (2.5 mg/L),  
462 probably not enough concentration to elicit any toxicity on *V.fischeri*.

### 463 **3.4 Monitoring of MTP, MTPA and TPs in HWW treated in a FBB bioreactor**

464 HWW was spiked with both MTP and MTPA at 2  $\mu\text{g/L}$  each in order to be able to follow  
465 the fate and transformation of both compounds in a fungal fluidized bed bioreactor  
466 using *G. lucidum* in realistic conditions (Maurer et al., 2007; Scheurer et al., 2010). This  
467 fungus was selected due to the optimal elimination percentages observed for MTP and  
468 MTPA in the flask experiments compared to the other fungi tested. Fig. 4 shows the  
469 presence of MTP and MTPA as well as the intermediates present in both liquid and  
470 solid phases at initial time and after 7 days of treatment. In contrast to the previous  
471 batch experiments under sterile conditions, in the bioreactor the fungus was competing  
472 against bacteria for nutrients. In addition, the presence of other contaminants (including  
473 pharmaceuticals) in the real HWW could affect fungus metabolism and growth.  
474 However, *G. lucidum* treatment was successfully implemented with real HWW and the  
475 elimination rates of MTP were rather similar: 33% of MTP elimination in the FBB  
476 bioreactor compared to the 35% obtained in flask experiments for the same period of  
477 time (7 days). Therefore, other factors involved (e.g. organic matter, bacteria, pollutant  
478 concentration among others) thus seemed not to interfere excessively in MTP  
479 elimination. In fact, MTPA removals in bioreactor were even higher than in batch  
480 experiments: 64% of MTPA elimination compared to the 46% obtained in flasks  
481 experiments. Although this extent on degradation of MTP was less than those values  
482 obtained in CAS experiments (Rubirola et al., 2014), the recalcitrant metabolite MTPA  
483 observed was successfully eliminated in fungal experiments. Likewise, direct sorption  
484 measures into biomass were also similar to those calculated in the previous flasks

485 experiments, up to 13% and 4% for MTP and MTPA respectively. These values are in  
486 accordance with those measured in the previous study reporting the greater sorption  
487 capabilities of *G. lucidum* than *T. versicolor* for pharmaceutical elimination in spiked  
488 synthetic medium (Lucas et al., 2018). In the present study, and for the first time, not  
489 only the target pollutants were investigated in solid phase biomass, but also the  
490 sorption of the different intermediates generated along FBB batch experiments.

491 Eleven out of sixteen intermediates detected in flasks experiments were also found in  
492 water and biomass samples from *G. lucidum* FBB experiments (Fig. 4). Most of them  
493 (O-DMTP, TP238, TP282A, TP298, TP300, TP316, TP226C, TP282B and TP134)  
494 were detected in water at low percentage values (< 5%) comparing to those values  
495 obtained in flasks experiments, except  $\alpha$ -HMTP at 15% from MTP degradation and  
496 TP240 at 6% also generated from MTPA elimination. After 7 days of treatment, most of  
497 the TP300 was detected in the biomass solid phase (11%) while  $\alpha$ -HMTP (28%) and  
498 TP240 (25%) were retained in less proportion in comparison to their presence in HWW  
499 liquid phase. These high levels may be related to the sorption of these TPs from liquid  
500 phase, but also to the transformation of MTP and MTPA occurring directly in the  
501 biomass phase. Regarding the transformation pathway, the extent on MTP and MTPA  
502 transformation did not go as far as in flask experiments: TP240 and  $\alpha$ -HMTP were still  
503 present at high level in FBB effluents (at 6% and 15%, respectively), while their further  
504 intermediates (TP254, TP282A and TP298; generated up to 15% in flasks experiments  
505 after 7 days of treatment, Fig. 3) were not detected in the same real effluents. Likewise,  
506 the relative presence of the residual TP134 in *G. lucidum* FBB experiments attained a  
507 percentage < 1%, lower than those obtained in pure water flasks experiments (4% and  
508 7% from MTP and MTPA degradation, respectively). This lower extent on TP  
509 transformation might be related to the presence of other contaminants competing on  
510 fungal degradation capacity, as well as natural organic matter. Otherwise, a slight  
511 increase on toxicity values about 36% (initial  $EC_{50}$  of 64% and final  $EC_{50}$  of 41%,

512 expressed in dilution percentage) after wastewater treatment was also observed. This  
513 might be associated to the transformation products of other contaminants present in  
514 HWW.

#### 515 **4. Conclusions**

516 Degradation, transformation and sorption capabilities of *Ganoderma lucidum*, *Trametes*  
517 *versicolor* and *Pleurotus ostreatus* fungi were investigated to evaluate the elimination of  
518 metoprolol and its recalcitrant metabolite metoprolol acid from water. Fourteen  
519 transformation products were detected as generated from MTP biodegradation and  
520 within them, five were identified as generated also from MTPA biotransformation. In  
521 addition, two TPs were specifically generated from MTPA biodegradation. Results  
522 revealed an increase on toxic effects along the fungal treatment of both MTP and  
523 MTPA, attributed to the TPs generated from their biodegradation. The maximum  
524 efficiency was achieved through *G. lucidum* with removals up to 51% and 77% for MTP  
525 and MTPA respectively (at 15 days of treatment) and therefore, this fungus was further  
526 selected for treating HWW in an aerobic fluidized bed bioreactor. Even though  
527 degradation rates achieved for MTP were quite similar to those obtained in Erlenmeyer  
528 flasks experiments, MTPA removals obtained were even better (64% at 7 days of  
529 treatment). However, the extent on compound transformation decreased, with the  
530 presence of less transformed and persistent intermediates such as TP240 and  $\alpha$ -  
531 HMTP, detected and highly eliminated through their generation and/or sorption into  
532 solid biomass phase. This is the first time that pharmaceutical TPs have been  
533 investigated in the biomass from fungal treatment. A slight increase on toxicity along  
534 water treatment was also observed in the experiments with real water, though, in this  
535 case, it is not easy to correlate with MTP and MTPA TPs formation, since many other  
536 TPs originated from the degradation of other contaminants can also be generated.

#### 537 **5. Acknowledgements**

538 This work was supported funded by the Spanish Ministry of Economy and  
539 Competitiveness (CTM2013-48548-C2), partly funded by the European Union through  
540 the European Regional Development Fund (ERDF) and supported by the Generalitat  
541 de Catalunya (Consolidate Research Group 2017 SGR 14, 2017 SGR 1404 and ICRA-  
542 ENV 2017 SGR 1124). The Department of Chemical, Biological and Environmental  
543 Engineering of the Universitat Autònoma de Barcelona is a member of the Xarxa de  
544 Referència en Biotecnologia de la Generalitat de Catalunya. A. Jaén-Gil acknowledges  
545 his PhD scholarship from AGAUR (2018FI\_B1\_00212), F. Castellet-Rovira  
546 acknowledges a predoctoral grant from UAB and S. Rodriguez-Mozaz acknowledges  
547 the Ramon y Cajal program (RYC- 2014-16707). We would like to thank Sant Joan de  
548 Déu Hospital staff for their collaboration during the sampling campaign.

#### 549 **References**

- 550 Asgher, M., Bhatti, H.N., Ashraf, M., Legge, R.L., 2008. Recent developments in  
551 biodegradation of industrial pollutants by white rot fungi and their enzyme system.  
552 *Biodegradation* 19, 771–783. doi:10.1007/s10532-008-9185-3
- 553 Barr, D.P., Aust, S.D., 1994. Mechanisms white rot fungi use to degrade pollutants.  
554 *Environ. Sci. Technol.* 28. doi:10.1021/es00051a002
- 555 Benner, J., Ternes, T.A., 2009. Ozonation of metoprolol: Elucidation of oxidation  
556 pathways and major oxidation products. *Environ. Sci. Technol.* 43, 5472–5480.  
557 doi:10.1021/es900280e
- 558 Blánquez, P., Casas, N., Font, X., Gabarrell, X., Sarrà, M., Caminal, G., Vicent, T.,  
559 2004. Mechanism of textile metal dye biotransformation by *Trametes versicolor*.  
560 *Water Res.* 38, 2166–2172. doi:10.1016/j.watres.2004.01.019
- 561 Bletsou, A.A., Jeon, J., Hollender, J., Archontaki, E., Thomaidis, N.S., 2015. Targeted



- 562 and non-targeted liquid chromatography-mass spectrometric workflows for  
563 identification of transformation products of emerging pollutants in the aquatic  
564 environment. *TrAC - Trends Anal. Chem.* 66, 32–44.  
565 doi:10.1016/j.trac.2014.11.009
- 566 Borg, K.O., Carlsson, E., Hoffmann, K. -J, Jönsson, T. -E, Thorin, H., Wallin, B., 1975.  
567 Metabolism of metoprolol-(3H) in man, the dog and the rat. *Acta Pharmacol.*  
568 *Toxicol. (Copenh).* 36, 125–135. doi:10.1111/j.1600-0773.1975.tb03329.x
- 569 Carraro, E., Bonetta, S., Bertino, C., Lorenzi, E., Bonetta, S., Gilli, G., 2016. Hospital  
570 effluents management: Chemical, physical, microbiological risks and legislation in  
571 different countries. *J. Environ. Manage.* 168, 185–199.  
572 doi:10.1016/j.jenvman.2015.11.021
- 573 Cavalcante, R.P., Dantas, R.F., Wender, H., Bayarri, B., González, O., Giménez, J.,  
574 Esplugas, S., Machulek, A., 2015. Photocatalytic treatment of metoprolol with B-  
575 doped TiO<sub>2</sub>: Effect of water matrix, toxicological evaluation and identification of  
576 intermediates. *Appl. Catal. B Environ.* 176–177, 173–182.  
577 doi:10.1016/j.apcatb.2015.04.007
- 578 ChemAxon Chemicalize Calculator [WWW Document], 2018. URL  
579 <https://www.chemaxon.com/> (accessed 3.20.18).
- 580 Cruz-Morató, C., Lucas, D., Llorca, M., Rodriguez-Mozaz, S., Gorga, M., Petrovic, M.,  
581 Barceló, D., Vicent, T., Sarrà, M., Marco-Urrea, E., 2014. Hospital wastewater  
582 treatment by fungal bioreactor: Removal efficiency for pharmaceuticals and  
583 endocrine disruptor compounds. *Sci. Total Environ.* 493, 365–376.  
584 doi:10.1016/j.scitotenv.2014.05.117
- 585 Escher, B.I., Bramaz, N., Richter, M., Lienert, J., 2006. Comparative ecotoxicological

- 586 hazard assessment of beta-blockers and their human metabolites using a mode-  
587 of-action-based test battery and a QSAR approach. *Environ. Sci. Technol.* 40,  
588 7402–7408. doi:10.1021/es052572v
- 589 Escher, B.I., Fenner, K., 2011. Recent advances in environmental risk assessment of  
590 transformation products. *Environ. Sci. Technol.* 45, 3835–3847.  
591 doi:10.1021/es1030799
- 592 Font, X., Caminal, G., Gabarrell, X., Romero, S., Vicent, M.T., 2003. Black liquor  
593 detoxification by laccase of *Trametes versicolor* pellets. *J. Chem. Technol.*  
594 *Biotechnol.* 78, 548–554. doi:10.1002/jctb.834
- 595 Godbillon, J., Duval, M., 1984. Determination of two metoprolol metabolites in human  
596 urine by high-performance liquid chromatography. *J. Chromatogr., B Biomed. Sci.*  
597 *Appl.* 309, 198–202.
- 598 Gros, M., Rodríguez-Mozaz, S., Barceló, D., 2012. Fast and comprehensive multi-  
599 residue analysis of a broad range of human and veterinary pharmaceuticals and  
600 some of their metabolites in surface and treated waters by ultra-high-performance  
601 liquid chromatography coupled to quadrupole-linear ion trap tandem. *J.*  
602 *Chromatogr. A* 1248, 104–121. doi:10.1016/j.chroma.2012.05.084
- 603 Hofrichter, M., Ullrich, R., Pecyna, M.J., Liers, C., Lundell, T., 2010. New and classic  
604 families of secreted fungal heme peroxidases. *Appl. Microbiol. Biotechnol.* 87,  
605 871–897. doi:10.1007/s00253-010-2633-0
- 606 Hughes, S.R., Kay, P., Brown, L.E., 2013. Global synthesis and critical evaluation of  
607 pharmaceutical data sets collected from river systems. *Environ. Sci. Technol.* 47,  
608 661–677. doi:10.1021/es3030148
- 609 ISO, 1998. ISO 11348-3:1998 - Water quality -- Determination of the inhibitory effect of

- 610 water samples on the light emission of *Vibrio fischeri* (Luminescent bacteria test).  
611 Int. Organ. Stand. (ISO),.
- 612 Jaén-Gil, A., Hom-Díaz, A., Llorca, M., Vicent, T., Blázquez, P., Barceló, D.,  
613 Rodríguez-Mozaz, S., 2018. An automated on-line turbulent flow liquid-  
614 chromatography technology coupled to a high resolution mass spectrometer LTQ-  
615 Orbitrap for suspect screening of antibiotic transformation products during  
616 microalgae wastewater treatment. *J. Chromatogr. A*.  
617 doi:10.1016/j.chroma.2018.06.027
- 618 Kern, S., Baumgartner, R., Helbling, D.E., Hollender, J., Singer, H., Loos, M.J.,  
619 Schwarzenbach, R.P., Fenner, K., 2010. A tiered procedure for assessing the  
620 formation of biotransformation products of pharmaceuticals and biocides during  
621 activated sludge treatment. *J. Environ. Monit.* 12, 2100. doi:10.1039/c0em00238k
- 622 Kirk, T.K., Schultz, E., Connors, W.J., Lorenz, L.F., Zeikus, J.G., 1978. Influence of  
623 Culture Parameters on Lignin Metabolism by *Phanerochaete chrysosporium*. *Arch.*  
624 *Microbiol.* 117, 277–285. doi:doi.org/10.1007/BF00738547
- 625 Koba, O., Golovko, O., Kodešová, R., Klement, A., Grabic, R., 2016. Transformation of  
626 atenolol, metoprolol, and carbamazepine in soils: The identification, quantification,  
627 and stability of the transformation products and further implications for the  
628 environment. *Environ. Pollut.* 218, 574–585. doi:10.1016/j.envpol.2016.07.041
- 629 Lacey, C., Basha, S., Morrissey, A., Tobin, J.M., 2012. Occurrence of pharmaceutical  
630 compounds in wastewater process streams in Dublin, Ireland. *Environ. Monit.*  
631 *Assess.* 184, 1049–1062. doi:10.1007/s10661-011-2020-z
- 632 Llorca, M., Castellet-Rovira, F., Farré, M.-J., Jaén-Gil, A., Martínez-Alonso, M.,  
633 Rodríguez-Mozaz, S., Sarrà, M., Barceló, D., 2018. Fungal biodegradation of the

- 634 NDMA precursors venlafaxine and O-desmethylvenlafaxine in water. Environ.  
635 Pollut. doi:10.1016/j.envpol.2018.12.008
- 636 Lucas, D., Castellet-Rovira, F., Villagrasa, M., Badia-Fabregat, M., Barceló, D., Vicent,  
637 T., Caminal, G., Sarrà, M., Rodríguez-Mozaz, S., 2018. The role of sorption  
638 processes in the removal of pharmaceuticals by fungal treatment of wastewater.  
639 Sci. Total Environ. 610–611, 1147–1153. doi:10.1016/j.scitotenv.2017.08.118
- 640 Ma, B., Huang, H.H., Chen, X.Y., Sun, Y.M., Lin, L.H., Zhong, D.F., 2007.  
641 Biotransformation of metoprolol by the fungus *Cunninghamella blakesleeana*. Acta  
642 Pharmacol. Sin. 28, 1067–1074. doi:10.1111/j.1745-7254.2007.00567.x
- 643 Mamo, J., García-Galán, M.J., Stefani, M., Rodríguez-Mozaz, S., Barceló, D., Monclús,  
644 H., Rodríguez-Roda, I., Comas, J., 2018. Fate of pharmaceuticals and their  
645 transformation products in integrated membrane systems for wastewater  
646 reclamation. Chem. Eng. J. 331, 450–461. doi:10.1016/j.cej.2017.08.050
- 647 Marco-Urrea, E., Pérez-Trujillo, M., Vicent, T., Caminal, G., 2009. Ability of white-rot  
648 fungi to remove selected pharmaceuticals and identification of degradation  
649 products of ibuprofen by *Trametes versicolor*. Chemosphere 74, 765–772.  
650 doi:10.1016/j.chemosphere.2008.10.040
- 651 Maurer, M., Escher, B.I., Richle, P., Schaffner, C., Alder, A.C., 2007. Elimination of  $\beta$ -  
652 blockers in sewage treatment plants. Water Res. 41, 1614–1622.  
653 doi:10.1016/j.watres.2007.01.004
- 654 Meunier, B., de Visser, S.P., Shaik, S., 2004. Mechanism of oxidation reactions  
655 catalyzed by cytochrome P450 enzymes. Chem. Rev. 104, 3947–3980.  
656 doi:10.1021/cr020443g
- 657 Palli, L., Castellet-Rovira, F., Pérez-Trujillo, M., Caniani, D., Sarrà-Adroguer, M., Gori,

- 658 R., 2017. Preliminary evaluation of *Pleurotus ostreatus* for the removal of selected  
659 pharmaceuticals from hospital wastewater. *Biotechnol. Prog.* 33, 1529–1537.  
660 doi:doi.org/10.1002/btpr.2520
- 661 Pauwels, B., Verstraete, W., 2006. The treatment of hospital wastewater: An appraisal.  
662 *J. Water Health* 4, 405–416. doi:10.2166/wh.2006.025
- 663 Radjenović, J., Pérez, S., Petrović, M., Barceló, D., 2008. Identification and structural  
664 characterization of biodegradation products of atenolol and glibenclamide by liquid  
665 chromatography coupled to hybrid quadrupole time-of-flight and quadrupole ion  
666 trap mass spectrometry. *J. Chromatogr. A* 1210, 142–153.  
667 doi:10.1016/j.chroma.2008.09.060
- 668 Ratola, N., Cincinelli, A., Alves, A., Katsoyiannis, A., 2012. Occurrence of organic  
669 microcontaminants in the wastewater treatment process. A mini review. *J. Hazard.  
670 Mater.* 239–240, 1–18. doi:10.1016/j.jhazmat.2012.05.040
- 671 Rodriguez-Mozaz, S., Lucas, D., Barceló, D., 2018. Full-scale plants for dedicated  
672 treatment of hospital effluents, in: *Handbook of Environmental Chemistry*.  
673 Springer, Berlin, Heidelberg, pp. 189–208. doi:10.1007/698\_2017\_13
- 674 Romero, V., Acevedo, S., Marco, P., Giménez, J., Esplugas, S., 2016a. Enhancement  
675 of Fenton and photo-Fenton processes at initial circumneutral pH for the  
676 degradation of the  $\beta$ -blocker metoprolol. *Water Res.* 88, 449–457.  
677 doi:10.1016/j.watres.2015.10.035
- 678 Romero, V., González, O., Bayarri, B., Marco, P., Giménez, J., Esplugas, S., 2016b.  
679 Degradation of Metoprolol by photo-Fenton: Comparison of different photoreactors  
680 performance. *Chem. Eng. J.* 283, 639–648. doi:10.1016/j.cej.2015.07.091
- 681 Romero, V., González, O., Bayarri, B., Marco, P., Giménez, J., Esplugas, S., 2015.


- 682 Performance of different advanced oxidation technologies for the abatement of the  
683 beta-blocker metoprolol. *Catal. Today* 240, 86–92.  
684 doi:10.1016/j.cattod.2014.03.060
- 685 Rubirola, A., Llorca, M., Rodriguez-Mozaz, S., Casas, N., Rodriguez-Roda, I., Barceló,  
686 D., Buttiglieri, G., 2014. Characterization of metoprolol biodegradation and its  
687 transformation products generated in activated sludge batch experiments and in  
688 full scale WWTPs. *Water Res.* 63, 21–32. doi:10.1016/j.watres.2014.05.031
- 689 Scheurer, M., Ramil, M., Metcalfe, C.D., Groh, S., Ternes, T.A., 2010. The challenge of  
690 analyzing beta-blocker drugs in sludge and wastewater. *Anal. Bioanal. Chem.*  
691 396, 845–856. doi:10.1007/s00216-009-3225-7
- 692 Slegers, C., Maquille, A., Deridder, V., Sonveaux, E., Habib Jiwan, J.L., Tilquin, B.,  
693 2006. LC-MS analysis in the e-beam and gamma radiolysis of metoprolol tartrate  
694 in aqueous solution: Structure elucidation and formation mechanism of radiolytic  
695 products. *Radiat. Phys. Chem.* 75, 977–989.  
696 doi:10.1016/j.radphyschem.2006.02.001
- 697 Šojić, D., Despotović, V., Orčić, D., Szabó, E., Arany, E., Armaković, S., Illés, E.,  
698 Gajda-Schranz, K., Dombi, A., Alapi, T., Sajben-Nagy, E., Palágyi, A., Vágvölgyi,  
699 C., Manczinger, L., Bjelica, L., Abramović, B., 2012. Degradation of thiamethoxam  
700 and metoprolol by UV, O<sub>3</sub> and UV/O<sub>3</sub> hybrid processes: Kinetics, degradation  
701 intermediates and toxicity. *J. Hydrol.* 472–473, 314–327.  
702 doi:10.1016/j.jhydrol.2012.09.038
- 703 Tay, K.S., Rahman, N.A., Abas, M.R. Bin, 2013. Ozonation of metoprolol in aqueous  
704 solution: Ozonation by-products and mechanisms of degradation. *Environ. Sci.*  
705 *Pollut. Res.* 20, 3115–3121. doi:10.1007/s11356-012-1223-3

- 706 Urlacher, V.B., Girhard, M., 2012. Cytochrome P450 monooxygenases: An update on  
707 perspectives for synthetic application. *Trends Biotechnol.* 30, 26–36.  
708 doi:10.1016/j.tibtech.2011.06.012
- 709 Verlicchi, P., Al Aukidy, M., Zambello, E., 2015. What have we learned from worldwide  
710 experiences on the management and treatment of hospital effluent? - An overview  
711 and a discussion on perspectives. *Sci. Total Environ.* 514, 467–491.  
712 doi:10.1016/j.scitotenv.2015.02.020
- 713 Verlicchi, P., Al Aukidy, M., Zambello, E., 2012. Occurrence of pharmaceutical  
714 compounds in urban wastewater: Removal, mass load and environmental risk  
715 after a secondary treatment-A review. *Sci. Total Environ.* 429, 123–155.  
716 doi:10.1016/j.scitotenv.2012.04.028
- 717 Verlicchi, P., Galletti, A., Petrovic, M., Barceló, D., 2010. Hospital effluents as a source  
718 of emerging pollutants: An overview of micropollutants and sustainable treatment  
719 options. *J. Hydrol.* 389, 416–428. doi:10.1016/j.jhydrol.2010.06.005
- 720 Wessjohann, L.A., Keim, J., Weigel, B., Dippe, M., 2013. Alkylating enzymes. *Curr.*  
721 *Opin. Chem. Biol.* 17, 229–235. doi:10.1016/j.cbpa.2013.02.016
- 722 Wharf, C., Kingdom, U., 2010. Questions and answers on ' Guideline on the  
723 environmental risk assessment of medicinal products for human use ' 2010, 1–9.
- 724 Wilde, M.L., Montipó, S., Martins, A.F., 2014. Degradation of  $\beta$ -blockers in hospital  
725 wastewater by means of ozonation and Fe<sup>2+</sup>/ozonation. *Water Res.* 48, 280–295.  
726 doi:10.1016/j.watres.2013.09.039
- 727


**Table 1.** Abiotic degradation, sorption and biodegradation percentages of MTP and MTPA along *G. lucidum* (GL), *T. versicolor* (TV) and *P. ostreatus* (PO) experiments along 15 days of treatment. Calculations were performed using Eq. (1), (2) and (3).

Degradation mechanism	Fungi	MTP				MTPA			
		0d	3d	10d	15d	0d	3d	10d	15d
Abiotic degradation (%)	-	0	0	0	0	0	1	4	3
Sorption (%)	GL	0	9	13	23	0	1	8	11
	TV	0	6	29	28	0	0	6	3
	PO	0	9	20	25	0	0	0	0
Biodegradation (%)	GL	0	6	34	28	0	19	50	63
	TV	0	5	11	21	0	9	39	48
	PO	0	10	6	0	0	20	21	32







**Fig. 1.** MTP, MTPA and TP relative presence ( $A/A_0$ )-(%) in water samples along the time from abiotic control and fungal conditions, both heat-killed control and fungal degradation experiments with *G. lucidum*, *T. versicolor* and *P. ostreatus*. Colored lines indicate the sum of TPs generated in fungal degradation experiments.



**Fig. 2.** Transformation pathways suggested of MTP (dotted orange lines) and its main metabolite MTPA (solid green lines) elucidated from *G. lucidum*, *T. Versicolor* and *P. ostreatus* fungal degradation experiments. MTP, MTPA and all intermediates identified except TP226B and TP226C may generate TP134.



**Fig. 3.** MTP, MTPA and TP relative presence ( $A/A_0$ )-(%) in abiotic control and fungal degradation experiments with *G. lucidum*, *T. versicolor* and *P. ostreatus* along 15 days of treatment. TPs are grouped based on their direct connection in degradation pathways.



**Fig. 4.** MTP, MTPA and TP relative presence in water and biomass at 0 and 7 days treating HWW in a FBB bioreactor. Calculations were performed using Eq.(4) and (5). TPs are grouped based on their direct connection in degradation pathways.

**Highlights:**

- Degradation, transformation and sorption of MTP and MTPA in fungal treatment.
- Satisfactory elimination of the recalcitrant metabolite MTPA, up to 77%.
- Tentative identification of 16 TPs from MTP and MTPA biotransformation.
- *G. lucidum* treating hospital wastewater in an aerobic fluidized bed bioreactor.
- Distribution of TPs between hospital wastewater and fungal biomass phases.

**Author's agreement**

We the undersigned declare that the manuscript entitled "Fungal treatment of metoprolol and its recalcitrant metabolite metoprolol acid in hospital wastewater: biotransformation, sorption and ecotoxicological impact" is original has not been full or partially published before, and is not currently being considered for publication elsewhere.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship that are not listed. We further confirm that the order of authors listed in the manuscript has been approved by the undersigned.

Signature of all authors:

Francesc Castellet-Rovira

MONTSERRAT  
SARRA  
ADROGUER -  
DNI 40312755B

Firmado digitalmente  
por MONTSERRAT  
SARRA ADROGUER -  
DNI 40312755B  
Fecha: 2018.12.20  
11:03:55 +01'00'

ACCEPTED

ACCEPTED

**Author's contribution**

A.J.G., S.R.M., F.C.R., M.L. and M.S. designed the experiment; F.C.R. carried out the fungal bioreactors; A.J.G. performed the sample treatment, chromatographic analysis and data processing; M.V. performed the bioassays; A.J.G. wrote the manuscript. All authors reviewed the manuscript and agree on the content.